Medical adhesive
    1.
    发明授权
    Medical adhesive 有权
    医用胶

    公开(公告)号:US08273847B2

    公开(公告)日:2012-09-25

    申请号:US10594627

    申请日:2005-03-23

    摘要: A medical adhesive comprises a hydrophilic urethane prepolymer (UP) obtained by reacting a fluorine-containing nonaromatic polyisocyanate component (A) and a polyol component (B) having a hydrophilic polyol (B1), and a phenolic radical scavenger (PRS). The content of (PRS) is preferably 0.01 to 3% by weight based on the weight of (UP). The content of oxyethylene groups in (B) is preferably 30 to 100% by weight based on the weight of the oxyalkylene groups in (B). Preferably, (B) is a mixture of a random copolymer obtained by addition of ethylene oxide and propylene oxide to diols and polypropylene glycol. The content of isocyanate groups in the medical adhesive is 1 to 10% by weight based on the weight of (UP). The medical adhesive is suitable for bonding body tissues, such as lung, artery and heart in particular.

    摘要翻译: 医用胶粘剂包括通过使含氟非芳族多异氰酸酯组分(A)和具有亲水多元醇(B1)的多元醇组分(B)和酚基清除剂(PRS)反应获得的亲水性氨基甲酸酯预聚物(UP)。 (PRS)的含量以(UP)的重量计优选为0.01〜3重量%。 (B)中的氧化乙烯基的含量相对于(B)中的氧化烯的重量优选为30〜100重量%。 优选地,(B)是通过在二醇和聚丙二醇中加入环氧乙烷和环氧丙烷得到的无规共聚物的混合物。 医用粘合剂中异氰酸酯基的含量为(UP)重量的1〜10重量%。 医用粘合剂特别适用于结合身体组织,如肺,动脉和心脏。

    Medical Adhesive
    2.
    发明申请
    Medical Adhesive 有权
    医用胶

    公开(公告)号:US20070282093A1

    公开(公告)日:2007-12-06

    申请号:US10594627

    申请日:2005-03-23

    IPC分类号: C07C271/06

    摘要: The present invention has its object to provide a medical adhesive excellent in safety, reactivity (curing rate) and duration of adhesive strength. A medical adhesive of the present invention comprises a hydrophilic urethane prepolymer (UP) obtained by reacting a fluorine-containing nonaromatic polyisocyanate component (A) and a polyol component (B) having a hydrophilic polyol (B1) as the essential component, and a phenolic radical scavenger (PRS). The content of (PRS) is preferably 0.01 to 3% by weight based on the weight of (UP). The content of oxyethylene groups in (B) is preferably 30 to 100% by weight based on the weight of the oxyalkylene groups in (B). Preferably, (B) is a mixture of a random copolymer obtained by addition of ethylene oxide and propylene oxide to diols and polypropylene glycol. The content of isocyanate groups in the medical adhesive is 1 to 10% by weight based on the weight of (UP). The medical adhesive of the present invention is suitable for bonding body tissues, such as lung, artery and heart in particular.

    摘要翻译: 本发明的目的是提供一种安全性,反应性(固化速度)和粘合强度持续时间优异的医用粘合剂。 本发明的医用粘合剂包含通过使含氟非芳香族多异氰酸酯成分(A)和具有亲水性多元醇(B 1)作为必要成分的多元醇成分(B)反应而得到的亲水性氨基甲酸酯预聚物(UP) 酚类清除剂(PRS)。 (PRS)的含量以(UP)的重量计优选为0.01〜3重量%。 (B)中的氧化乙烯基的含量相对于(B)中的氧化烯的重量优选为30〜100重量%。 优选地,(B)是通过在二醇和聚丙二醇中加入环氧乙烷和环氧丙烷得到的无规共聚物的混合物。 医用粘合剂中异氰酸酯基的含量为(UP)重量的1〜10重量%。 本发明的医用粘合剂特别适用于结合身体组织,如肺,动脉和心脏。

    Cell-containing preparations
    5.
    发明申请
    Cell-containing preparations 审中-公开
    含细胞的制剂

    公开(公告)号:US20060228344A1

    公开(公告)日:2006-10-12

    申请号:US10559835

    申请日:2004-01-23

    申请人: Takehisa Matsuda

    发明人: Takehisa Matsuda

    IPC分类号: A61K48/00 C12N15/86

    摘要: The present invention provides a cell-containing preparation comprising cells containing a DNA having a base sequence represented by SEQ ID NO:1 or 2, or a DNA hybridizable with a DNA having a base sequence represented by SEQ ID NO:1 or 2 under stringent conditions, and a fibrous protein. The cell-containing preparation of the present invention makes it possible to more efficiently supply NK4 having an inhibitory action against the growth or metastasis of cancers to cancer cells.

    摘要翻译: 本发明提供一种含有细胞的制剂,其含有含有由SEQ ID NO:1或2表示的碱基序列的DNA的细胞,或者与具有由SEQ ID NO:1或2表示的碱基序列的DNA杂交的DNA在严格条件下 条件和纤维蛋白。 本发明的含细胞的制剂使得可以更有效地提供对癌细胞的生长或转移具有抑制作用的NK4。

    Artificial blood vessel and process for producing the same
    6.
    发明授权
    Artificial blood vessel and process for producing the same 失效
    人造血管及其制造方法

    公开(公告)号:US5718723A

    公开(公告)日:1998-02-17

    申请号:US305377

    申请日:1994-09-13

    摘要: This invention provides a more functionalized artificial blood vessel which can be organized by independently designing its inner and outer surfaces and endowing them with respectively different biocompatibilities, as well as a process for producing the same. The artificial blood vessel comprises a tubular support having a layer of photogelled cinnamic acid-bound chondroitin sulfate coated on the inner surface thereof and a layer of photogelled coumarin-bound gelatin coated on the outer surface thereof. The process for producing the above artificial blood vessel comprises coating a layer of coumarin-bound gelatin on the outer surface of a tubular support and a layer of cinnamic acid-bound chondroitin sulfate on the inner surface of the support and irradiating each of the layers with light.

    摘要翻译: 本发明提供了一种更具功能化的人造血管,其可以通过独立地设计其内表面和外表面并赋予它们分别具有不同的生物相容性以及其制造方法来组织。 人造血管包括管状支持体,其具有涂覆在其内表面上的光凝胶状肉桂酸结合的硫酸软骨素层和涂覆在其外表面上的光凝胶化香豆素结合明胶层。 制造上述人造血管的方法包括在支撑体的内表面上在管状载体的外表面上涂布香豆素结合的明胶层,并在载体的内表面上涂布肉桂酸结合的硫酸软骨素层,并用 光。

    Immobilization of an anti-thrombogenic substance with a photo-reactive
azide and a photo-crosslinking material
    7.
    发明授权
    Immobilization of an anti-thrombogenic substance with a photo-reactive azide and a photo-crosslinking material 失效
    用光反应性叠氮化物和光交联材料固定抗血栓形成物质

    公开(公告)号:US5348873A

    公开(公告)日:1994-09-20

    申请号:US963089

    申请日:1992-10-19

    摘要: An anti-thrombogenic substance is immobilized on a base of a medical device to impart anti-thrombogenic properties to the medical device. The method comprises the steps of applying a photo-reactive azide derivative macromolecular material to a base to form a bonding layer, coating the bonding layer with a macromolecular layer composed of a water-soluble photo-crosslinking macromolecular material containing the anti-thrombogenic substance, and irradiating the base with ultraviolet light with the bonding layer and the macromolecular layer formed thereon to develop inter-molecular covalent bonding in the bonding layer. The macromolecular layer containing the anti-thrombogenic substance is thus fixed onto the base. Concurrently, the anti-thrombogenic substance is immobilized in the macromolecular layer which is crosslinked. The azide derivative can be poly-m-azidostyrene, copolymers, of poly-m-aziodstyrene with styrene and copolymers of poly-m-azidostyrene with methyl methacrylate. The water-soluble photo-crosslinking macromolecular material can be a copolymer of a photo-dimeric monomer with a water-soluble monomer or a copolymer of a photo-reactive azide with a water-soluble monomer.

    摘要翻译: 将抗血栓形成物质固定在医疗装置的基底上,以向医疗装置赋予抗血栓形成性质。 该方法包括以下步骤:将光反应性叠氮化物衍生物高分子材料施加到基底上以形成结合层,用包含抗血栓形成物质的水溶性光交联性高分子材料构成的高分子层涂覆粘合层, 并用形成在其上的接合层和高分子层的紫外线照射基底,以在接合层中形成分子间共价键。 因此将含有抗血栓形成物质的大分子层固定在基底上。 同时,抗血栓形成物质固定在交联的高分子层中。 叠氮衍生物可以是聚 - 间 - 叠氮基苯乙烯,聚 - 间 - 偶氮苯乙烯与苯乙烯的共聚物和聚 - 叠氮基苯乙烯与甲基丙烯酸甲酯的共聚物。 水溶性光交联高分子材料可以是光二聚单体与水溶性单体或光反应性叠氮化物与水溶性单体的共聚物的共聚物。